Evidence-based review of clinical outcomes of guideline-recommended pharmacotherapies for generalized anxiety disorder

Canadian Journal of Psychiatry

Volumn 57, Issue 8, 2012, Pages 470-478

  Bereza, Basil G ^a   MacHado, Márcio ^a   Ravindran, Arun V ^a,b   Einarson, Thomas R ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Anxiety; Metaanalysis; Pharmacotherapy

Indexed keywords

ARTICLE; DRUG CLASSIFICATION; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; REMISSION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84873020837     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371205700805     Document Type: Article

References (62)

1. Canadian Psychiatric Association. Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatry. 2006;51(8 Suppl 2):7S-91S.
2. Katz I, Reynolds C, Alexopoulos G, et al. Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials. J Am Geriatr Soc. 2002;50:18-22.
3. Mitte K, Noack P, Steil R, et al. A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder. J Clin Psychopharmacol. 2005;25:141-150.
4. Kapczinski F, Lima MS, Souza JS, et al. Antidepressants for generalized anxiety disorder. Cochrane Database Syst Rev. 2003;(2):CD003592.
5. Goodman WK, Bose A, Wang Q. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord. 2005;87:161-167.
6. Davidson JRT, Bose A, Su G. Escitalopram in the treatment of generalized anxiety disorder. Poster presented at the 22nd National Conference of the Anxiety Disorders Association of America; 2002 Mar 21-24; Austin (TX).
7. Hackett D, Desmet A, Salinas EO. Dose-response efficacy of longterm treatment of venlafaxine extended-release in generalized anxiety disorder. J Eur Coll Neuropsychopharmacol. 1999;9(Suppl 5):315.
8. Hackett D, Salinas E, Rudolph RL, et al, for the Venlafaxine XR 378 Study Group. [title unknown] (Abstract) [place of publicationunknown]: Anxiety and Depression Association of America; 1999. This reference came about while hand-searching for articles to include in the meta-analysis. Other publications cite this abstract in this manner. This abstract was not retrievable.
9. Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twentyfour-week placebo-controlled dose-ranging study. Br J Psychiatry. 2001;179:15-22.
10. Allgulander C, Dahl AA, Austin C, et al. Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry. 2004;161:1642-1649.
11. Baldwin DS, Huusom AK, Maehlum E. Escitalopram and paroxetine in the treatment of generalised anxiety disorder. Br J Psychiatry. 2006;189:264-272.
12. Ball SG, Kuhn A, Wall D, et al. Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. J Clin Psychiatry. 2005;66:94-99.
13. Bielski RJ, Bose A, Chang CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry. 2005;17:65-69.
14. Davidson JR, DuPont RL, Hedges D, et al. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry. 1999;60:528-535.
15. Davidson JR, Bose A, Korotzer A, et al. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety. 2004;19:234-240.
16. Gelenberg AJ, Lydiard RB, Rudolph RL, et al. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder. JAMA. 2000;283:3082-3088.
17. Nimatoudis I, Zissis NP, Kogeorgos J, et al. Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study. Int Clin Psychopharmacol. 2004;19:331-336.
18. Pollack MH, Zaninelli R, Goddard A, et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebocontrolled, flexible-dosage trial. J Clin Psychiatry. 2001;62:350-357.
19. Rickels K, Pollack MH, Sheehan DV, et al. Efficacy of extended release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry. 2000;157:968-974.
20. Rickels K, Zaninelli R, McCafferty J, et al. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2003;160:749-756.
21. Rocca P, Fonzo V, Scotta M, et al. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand. 1997;95:444-450.
22. Silverstone PH, Salinas E. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. J Clin Psychiatry. 2001;67:523-529.
23. Feltner DE, Crockatt JG, Dubovsky SJ, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2003;23:240-249.
24. Pohl RB, Feltner DE, Fieve RR, et al. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol. 2005;25:151-158.
25. Rickels K, Pollack MH, Feltner DE, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry. 2005;62:1022-1030.
26. Enkelmann R. Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology (Berl). 1991;105:428-432.
27. Goldberg HL, Finnerty R. Comparison of buspirone in two separate studies. J Clin Psychiatry. 1982;43:87-91.
28. Laakmann G, Schüle C, Lorkowski G, et al. Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients. Psychopharmacology (Berl). 1998;136:357-366.
29. Lader M, Scotto JC. A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology (Berl). 1998;139:402-406.
30. Pollack MH, Worthington JJ, Manfro GG, et al. Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone. J Clin Psychiatry. 1997;58(Suppl 11):19-23.
31. Sramek JJ, Tansman M, Suri A, et al. Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms. J Clin Psychiatry. 1996;57:287-291.
32. Tollefson GD, Montague-Clouse J, Tollefson SL. Treatment of comorbid generalized anxiety in a recently detoxified alcoholic population with a selective serotonergic drug (buspirone). J Clin Psychopharmacol. 1992;12:19-26.
33. Castillo A, Sotillo C, Mariategui J. Alprazolam compared to clobazam and placebo in anxious outpatients. Neuropsychobiology. 1987;18:189-194.
34. Cohn JB, Wilcox CS. Long-term comparison of alprazolam, lorazepam and placebo in patients with an anxiety disorder. Pharmacotherapy. 1984;4:93-98.
35. Lydiard RB, Ballenger JC, Rickels K. A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. Abecarnil Work Group. J Clin Psychiatry. 1997;58(Suppl 11):11-18.
36. Möller HJ, Volz HP, Reimann IW, et al. Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J Clin Psychopharmacol. 2001;21:59-65.
37. Fontaine R, Annable L, Chouinard G, et al. Bromazepam and diazepam in generalized anxiety: a placebo-controlled study with measurement of drug plasma concentrations. J Clin Psychopharmacol. 1983;3:80-87.
38. Fontaine R, Mercier P, Beaudry P, et al. Bromazepam and lorazepam in generalized anxiety: a placebo-controlled study with measurement of drug plasma concentrations. Acta Psychiatr Scand. 1986;74:451-458.
39. Llorca PM, Spadone C, Sol O, et al. Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study. J Clin Psychiatry. 2002;63:1020-1027.
40. Boyer WF, Feighner JP. A placebo-controlled double-blind multicenter trial of two doses of ipsapirone versus diazepam in generalized anxiety disorder. Int Clin Psychopharmacol. 1993;8:173-176.
41. Pourmotabbed T, McLeod DR, Hoehn-Saric R, et al. Treatment, discontinuation, and psychomotor effects of diazepam in women with generalized anxiety disorder. J Clin Psychopharmacol. 1996;16:202-207.
42. Power KG, Jerrom DWA, Simpson RJ, et al. A controlled comparison of cognitive-behaviour therapy, diazepam and placebo in the treatment of generalized anxiety. Behav Psychother. 1989;17:1-14.
43. Rickels K, Downing R, Schweizer E, et al. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry. 1993;50:884-895.
44. Rickels K, Schweizer E, DeMartinis N, et al. Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trial. J Clin Psychopharmacol. 1997;17:272-277.
45. Rickels K, DeMartinis N, Aufdembrinke B. A double-blind, placebocontrolled trial of abecarnil and diazepam in the treatment of patients with generalized anxiety disorder. J Clin Psychopharmacol. 2000;20:12-18.
46. Fresquet A, Sust M, Lloret A, et al. Efficacy and safety of lesopitron in outpatients with generalized anxiety disorder. Ann Pharmacother. 2000;34:147-153.
47. Cutler NR, Sramek JJ, Keppel Hesselink JM, et al. A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial. J Clin Psychopharmacol. 1993;13:429-437.
48. Pollack MH, Simon NM, Zalta AK, et ak. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry. 2006;59:211-215.
49. Brawman-Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2005;66:1321-1325.
50. Gambi F, De Berardis D, Campanella D, et al. Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study. J Psychopharmacol. 2005;19:483-487.
51. Varia I, Rauscher F. Treatment of generalized anxiety disorder with citalopram. Int Clin Psychopharmacol. 2002;17:103-107.
52. Machado M, Iskedjian M, Ruiz I, et al. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Curr Med Res Opin. 2006;22:1825-1837.
53. Cipriani A, Geddes JR, Furukawa TA, et al. Metareview on shortterm effectiveness and safety of antidepressants for depression: an evidence-based approach to inform clinical practice. Can J Psychiatry. 2007;52:553-562.
54. Fontaine R, Chouinard G, Annable L. Bromazepam and diazepam in generalized anxiety: a placebo-controlled study of efficacy and withdrawal. Psychopharmacol Bull. 1984;20:126-127.
55. Fontaine R, Beaudry P, Beauclair L, et al. Comparison of withdrawal of buspirone and diazepam: a placebo controlled study. Prog Neuropsychopharmacol Biol Psychiatry. 1987;11(2-3):189-197.
56. Pecknold JC, Matas M, Howarth BG, et al. Evaluation of buspirone as an antianxiety agent: buspirone and diazepam versus placebo. Can J Psychiatry. 1989;34:766-770.
57. Power KG, Simpson RJ, Swanson V, et al. A controlled comparison of cognitive-behaviour therapy, diazepam, and placebo, alone and in combination, for the treatment of generalised anxiety disorder. J Anxiety Disord. 1990;4:267-292.
58. Tollefson GD, Lancaster SP, Montague-Clouse J. The association of buspirone and its metabolite 1-pyrimidinylpiperazine in the remission of comorbid anxiety with depressive features and alcohol dependency. Psychopharmacol Bull. 1991;27:163-170.
59. Bystritsky A, Kerwin L, Eiduson S, et al. A pilot controlled trial of bupropion vs es-citalopram in generalized anxiety disorder (GAD). Neuropsychopharmacology. 2005;30(Suppl 1):S101.
60. Hoehn-Saric R, McLeod DR, Zimmerli WD. Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J Clin Psychiatry. 1988;49:293-301.
61. Blair A, Burg J, Foran J, et al. Guidelines for application of metaanalysis in environmental epidemiology. ISLI Risk Science Institute. Regul Toxicol Pharmacol. 1995;22:189-197.
62. Sutton AJ, Abrams KR, Jones DR, et al, editors. Methods for metaanalysis in medical research. Vol 3. Hoboken (NJ): John Wiley & Sons, Ltd; 2004. p 53.